SeaCrest Wealth Management LLC Invests $26,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO)

SeaCrest Wealth Management LLC purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) during the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 53 shares of the medical research company’s stock, valued at approximately $26,000.

Several other hedge funds have also made changes to their positions in the business. Advisors Asset Management Inc. increased its stake in shares of Bio-Rad Laboratories by 51.0% during the second quarter. Advisors Asset Management Inc. now owns 3,610 shares of the medical research company’s stock worth $1,787,000 after buying an additional 1,219 shares during the period. Baird Financial Group Inc. increased its stake in shares of Bio-Rad Laboratories by 9.2% during the second quarter. Baird Financial Group Inc. now owns 2,179 shares of the medical research company’s stock worth $1,078,000 after buying an additional 184 shares during the period. Metis Global Partners LLC purchased a new stake in shares of Bio-Rad Laboratories during the second quarter worth approximately $208,000. Kentucky Retirement Systems Insurance Trust Fund increased its stake in shares of Bio-Rad Laboratories by 15.8% during the second quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 739 shares of the medical research company’s stock worth $366,000 after buying an additional 101 shares during the period. Finally, Kentucky Retirement Systems increased its stake in shares of Bio-Rad Laboratories by 16.6% during the second quarter. Kentucky Retirement Systems now owns 1,606 shares of the medical research company’s stock worth $795,000 after buying an additional 229 shares during the period. Institutional investors and hedge funds own 64.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on BIO. Credit Suisse Group dropped their price target on shares of Bio-Rad Laboratories from $715.00 to $640.00 and set an “outperform” rating on the stock in a research note on Friday, October 28th. TheStreet lowered shares of Bio-Rad Laboratories from a “c” rating to a “d+” rating in a research note on Thursday, October 27th. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, November 9th. One analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $680.00.

Bio-Rad Laboratories Price Performance

BIO stock opened at $403.94 on Thursday. The company has a market capitalization of $12.05 billion, a P/E ratio of -2.00 and a beta of 0.92. Bio-Rad Laboratories, Inc. has a twelve month low of $344.63 and a twelve month high of $771.69. The business has a 50 day simple moving average of $405.55 and a 200-day simple moving average of $473.70. The company has a current ratio of 5.50, a quick ratio of 4.30 and a debt-to-equity ratio of 0.14.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last posted its quarterly earnings data on Thursday, October 27th. The medical research company reported $2.60 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.01. The business had revenue of $680.10 million during the quarter, compared to the consensus estimate of $685.50 million. Bio-Rad Laboratories had a positive return on equity of 4.13% and a negative net margin of 215.16%. The company’s revenue was down 9.0% compared to the same quarter last year. During the same period in the prior year, the company earned $3.71 earnings per share. As a group, equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 14.38 EPS for the current year.

About Bio-Rad Laboratories

(Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Read More

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.